Cryoport, Inc. announced that its validated cryogenic logistics solutions are supporting Gradalis, Inc.'s clinical trials to evaluate its investigational Vigil® Engineered Autologous Tumor Cell (EATC) cellular immunotherapy technology for use in cancer treatments. Cryoport is currently supporting Gradalis' phase 2/3 trial for high risk stage III/IV ovarian cancer patients, its randomized Phase 2b trial for Ewing's sarcoma, as well as the pilot combination studies with PD-1/PD-L1 inhibitors, all of which utilize the Vigil bi-shRNA furin and GMCSF. Cryoport's global distribution network will provide the required cryogenic logistics support for multiple participating clinical sites located throughout the U.S. Cryoport's cryogenic cold chain logistics solutions will extend access to patients currently enrolled in the trials.